1V-LSD

Discovery

LSD was synthesized by Albert Hofmann at Sandoz Laboratories in 1938; its psychedelic properties emerged during accidental self-exposure on April 19, 1943.^[4] The first N1-acyl derivative, ALD-52 (1-acetyl-LSD), was synthesized at Sandoz in the 1950s by Stoll and coworkers.^[5] ALD-52 produced psychedelic effects similar to LSD — an observation later explained by prodrug hydrolysis rather than direct receptor activity.

The N1-Acyl Lysergamide Series

Starting in the mid-2010s, a succession of N1-acyl LSD derivatives entered the online research chemical market, each extending the acyl chain by one carbon: ALD-52 (C2) → 1P-LSD (C3) → 1B-LSD (C4) → 1V-LSD (C5) → 1H-LSD (C6) → 1DD-LSD (C12).^[3][6][5] Each new compound appeared after Germany's NpSG scheduled its predecessor, with vendors pivoting to the next unscheduled homolog. The series was systematically characterized in the "Return of the Lysergamides" publications by Brandt, Kavanagh, Halberstadt, and collaborators.^{[7][8][9][10][3]}

Market Appearance

1V-LSD entered the market around 2020–2021 and was analytically characterized in 2022 as Part VII of that series.^[3] The compound was subsequently detected in blotter products in Japan, marking the first identification of multi-position-modified LSD analogs in Japanese drug markets.^[11] A validated forensic detection method was developed, though no positive specimens were found among 325 urine samples tested.^[12]

Structure

1V-LSD belongs to the lysergamide family — ergoline alkaloids built on the tetracyclic indole-fused quinoline ring system of lysergic acid. The compound is derived from LSD by attaching a pentanoyl (valeroyl, C₅H₉O) group to the N1 indole nitrogen, making it the C5 member of the N1-acyl LSD series.^[3]

The molecule retains the diethylamide group at C9 and the N6-methyl group characteristic of active d-lysergamides. Its (6aR,9R) configuration corresponds to the dextrorotatory series — the biologically active form. The l-lysergamide epimer is pharmacologically inactive; epimerization under basic or thermal conditions is a known degradation pathway.citation needed

Stability and Handling

No published data on melting point, solubility, or crystalline form exist for 1V-LSD. By analogy with related N1-acyl derivatives, the compound is susceptible to hydrolysis under acidic conditions and in alcoholic solvents.^[13][14] The pentanoyl group may offer greater steric protection of the N1-acyl bond than the shorter acetyl group of ALD-52.^[14]

Methanol extraction causes artifact conversion of N1-acyl LSD derivatives to LSD, complicating forensic identification.^[14] No academic synthesis paper has been published; the compound is presumed to be synthesized from d-LSD via acylation with valeric anhydride or valeryl chloride.

Structure-Activity Relationships

1V-LSD sits in a homologous series where each derivative extends the N1-acyl chain by one carbon. Across the series, N1-acylation reduces receptor affinity by 1–2 orders of magnitude relative to LSD, converting each compound from an active psychedelic to a functionally inert precursor that requires hydrolysis to liberate LSD.^[1] The longer the acyl chain, the greater the steric bulk shielding the N1 position — a factor that may influence both hydrolysis rate and chemical stability.

Mechanism of Action

1V-LSD functions as a prodrug for LSD. N1-acyl substitution eliminates direct receptor activity, converting the compound to a functionally inert precursor that must be hydrolyzed in the body to release LSD.^[1] No direct binding or biotransformation data have been published for 1V-LSD itself; the prodrug hypothesis rests on converging evidence from structurally related derivatives.^[3]

The evidence for prodrug conversion across the N1-acyl class is strong. Incubation of 1CP-LSD with human serum produces LSD.^[10] After oral administration of 100 µg 1P-LSD to two volunteers, only LSD was detected in blood and urine — not 1P-LSD itself — with LSD bioavailability "close to 100%".^[15] Similar conversion has been confirmed for 1F-LSD and 1T-LSD in mice.^[16] The enzymes responsible include liver cytochrome P450s and plasma carboxylesterases,^[17] though the specific enzymes that hydrolyze 1V-LSD have not been identified.

In the mouse head-twitch response assay — a 5-HT₂A-mediated behavior validated as a predictor of hallucinogenic potency in humans^[18] — 1V-LSD showed an ED₅₀ of 373 nmol/kg, roughly one-third the potency of LSD (ED₅₀ = 132.8 nmol/kg).^[3] The reduced potency likely reflects incomplete hydrolysis rather than direct receptor activity.^[3]

Once liberated, LSD acts primarily as a partial agonist at the 5-HT₂A receptor. The 5-HT₂A antagonist ketanserin completely blocks all subjective LSD effects at 40 mg,^[2] confirming that this receptor is both necessary and sufficient for the psychedelic experience.

Pharmacokinetics

No human or animal pharmacokinetic data have been published for 1V-LSD itself.^[3] Following prodrug conversion, LSD pharmacokinetics apply.

LSD oral bioavailability is approximately 80%, with base and tartrate formulations performing equivalently.^[19] Peak plasma levels are reached 1–2.5 hours after ingestion. Half-life ranges from approximately 2.7 hours at microdoses to 5.7–6.4 hours at 100 µg,^[15] and extends up to 11.6 hours in individuals who are slow CYP2D6 metabolizers.^[20] Slow metabolizers experience approximately 75% higher overall LSD exposure and prolonged subjective effects.^[20]

The primary urinary metabolite of LSD is 2-oxo-3-hydroxy-LSD.^[21] LSD is detectable in urine for approximately 80 hours after a 100 µg dose. By analogy with 1P-LSD — where the parent compound was detectable in serum for only about 4 hours post-dose^[15] — 1V-LSD itself is expected to have a short plasma half-life, with LSD as the principal circulating active species.

Where It Acts

No direct neuroimaging data exist for 1V-LSD. As a prodrug for LSD, its neural effects are inferred from LSD research. LSD disrupts the default mode network (DMN) — the brain system underlying self-referential thought — and reduced DMN connectivity correlates directly with the experience of ego dissolution.citation needed Simultaneously, LSD opens thalamocortical gating, the brain's sensory filter, flooding the cortex with information normally suppressed and producing the visual intensification and sensory overload characteristic of the experience.citation needed

LSD also increases global functional connectivity: brain regions that normally communicate weakly begin exchanging information freely, accompanied by increased neural entropy — greater randomness in neural signaling that maps to loosened conceptual boundaries and novel associations.citation needed

Why It Matters

The REBUS (Relaxed Beliefs Under Psychedelics) model offers the most comprehensive framework: LSD relaxes the brain's confidence in its existing models of reality, allowing raw sensory data to override established expectations.citation needed This accounts for visual distortions, ego dissolution, and emotional lability across dose ranges.

LSD also promotes structural neuroplasticity through two independent pathways — classical 5-HT₂A signaling that drives dendritic growth, and direct binding to the TrkB receptor with approximately 1,000-fold higher affinity than conventional antidepressants.^[22] Whether 1V-LSD drives neuroplasticity at the same magnitude depends on the completeness of prodrug conversion.

Toxicity

An intoxication case involving 1P-LSD found LSD in serum and urine with the parent compound undetected, consistent with complete prodrug conversion.^[13]

Psychological Risks

In controlled settings, 200 µg LSD produced significant anxiety in healthy volunteers.^[2] Positive effects plateau around 100 µg while ego dissolution and anxiety continue to increase with dose.^[2] Uncontrolled settings amplify the risk of adverse reactions.

Hallucinogen persisting perception disorder (HPPD) is a rare condition in which perceptual disturbances re-emerge after the drug has cleared.^[24][25] LSD is the most frequently implicated substance in HPPD case reports.^[26] Prevalence estimates range from up to 39.7% for brief, mild disturbances to 4.3% for persistent symptoms with functional impairment.^[25] Treatment options include clonazepam or lamotrigine; antipsychotics are generally ineffective.^[26]

Individuals with personal or family history of psychotic disorders are at elevated risk for acute and potentially prolonged psychotic episodes following exposure to LSD-class compounds. This risk applies to 1V-LSD by class inference.

Tolerance & Dependence

Rapid tolerance develops within hours of a single dose through 5-HT₂A downregulation.^[4] Cross-tolerance is well-established among LSD, psilocybin, mescaline, and other serotonergic psychedelics.^[4] Full tolerance reset requires approximately 14 days.citation needed

No physical dependence has been documented for LSD in humans.^[4] Psychological dependence is rare. A meta-analysis of psychedelic clinical trials found no association between psychedelics and higher discontinuation rates.^[27]

Drug Interactions

Tramadol: Classified as dangerous.safety citation needed Tramadol combines weak opioid activity with serotonin reuptake inhibitor. Co-administration with LSD (following 1V-LSD conversion) raises the risk of serotonin syndrome and lowers the seizure threshold.

MAOIs: Risk of serotonin syndrome; may also potentiate and prolong LSD effects by inhibiting serotonin metabolism.

SSRIs/SNRIs: May blunt psychedelic effects through receptor-level competition. At high SSRI doses combined with serotonergic psychedelics, serotonin syndrome risk increases.

Lithium: Anecdotal reports associate LSD + lithium with seizures and cardiac events.safety citation needed The combination is flagged as high-risk in harm reduction literature.

CYP2D6 inhibitors: Fluoxetine, paroxetine, and bupropion may increase LSD exposure following 1V-LSD conversion by inhibiting the primary metabolic clearance pathway.^[20]

Cannabis: Interaction not well characterized. Preliminary evidence suggests THC may enhance psychedelic effects through 5-HT₂A signaling modulation.citation needed Practical significance with 1V-LSD is unstudied.

Contraindications

Psychotic disorders: Personal or family history of schizophrenia, schizoaffective disorder, or other psychotic illness is an absolute contraindication. LSD-class compounds can precipitate acute psychotic episodes and may accelerate onset in predisposed individuals.

Bipolar disorder: Relative contraindication. Psychedelic-induced mood destabilization may trigger manic or mixed episodes, particularly in unmedicated individuals.

Lithium use: Absolute contraindication due to reports of seizures and cardiac events.safety citation needed

Epilepsy: Relative contraindication. Seizure threshold modulation by serotonergic psychedelics is pharmacologically plausible but poorly documented.

Pregnancy: Absolute contraindication. No reproductive toxicity data exist for 1V-LSD. The risk-benefit ratio is categorically unfavorable.

Severe cardiovascular disease: Relative contraindication. LSD's sympathomimetic and vasoconstrictive effects pose theoretical risk in individuals with severe high blood pressure, coronary artery disease, or irregular heart rhythms.

1V-LSD occupies a legal grey area in most jurisdictions. It is not specifically scheduled in most countries, but its structural relationship to LSD — a universally controlled substance — exposes it to structural analog legislation and blanket psychoactive substance bans. Germany is the sole jurisdiction with a substance-specific legislative history.

Analog and Prodrug Considerations

The prodrug relationship between 1V-LSD and LSD complicates legal classification. In jurisdictions with analog legislation — notably the US Federal Analogue Act — the argument that 1V-LSD is "substantially similar" to LSD in both structure and pharmacological effect is straightforward: the compound is designed to produce LSD in the body. However, analog act prosecutions require proof of intent for human consumption and are applied case-by-case.

The German legislative history illustrates the regulatory challenge posed by structurally iterative designer drug development. Each scheduling action prompted a market pivot to the next unscheduled homolog in the series.